When former Turing Pharmaceuticals CEO Martin Shkreli appeared before the House Committee on Oversight and Government Reform in 2016, the most notable thing about his testimony was the smirk on his face as he refused to answer representatives’ questions about Turing’s $13.50 to $750 price hike for Daraprim, an anti-AIDS drug. Last week, it was Robinhood CEO […]